Biological properties of a specific Galpha q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress

British Journal of Pharmacology
Toshio UemuraKeiji Miyata

Abstract

1 The effects of YM-254890, a specific Galpha(q/11) inhibitor, on platelet functions, thrombus formation under high-shear rate condition and femoral artery thrombosis in cynomolgus monkeys were investigated. 2 YM-254890 concentration dependently inhibited ADP-induced intracellular Ca(2+) elevation, with an IC(50) value of 0.92+/-0.28 microM. 3 P-selectin expression induced by ADP or thrombin receptor agonist peptide (TRAP) was strongly inhibited by YM-254890, with IC(50) values of 0.51+/-0.02 and 0.16+/-0.08 microM, respectively. 4 YM-254890 had no effect on the binding of fibrinogen to purified GPIIb/IIIa, but strongly inhibited binding to TRAP-stimulated washed platelets. 5 YM-254890 completely inhibited platelet shape change induced by ADP, but not that induced by collagen, TRAP, arachidonic acid, U46619 or A23187. 6 YM-254890 attenuated ADP-, collagen-, TRAP-, arachidonic acid- and U46619-induced platelet aggregation with IC(50) values of <1 microM, whereas it had no effect on phorbol 12-myristate 13-acetate-, ristocetin-, thapsigargin- or A23187-induced platelet aggregation. 7 High-shear stress-induced platelet aggregation and platelet-rich thrombus formation on a collagen surface under high-shear flow conditions were conc...Continue Reading

References

Apr 1, 1991·The Journal of Clinical Investigation·Y IkedaI Itagaki
Mar 1, 1994·British Journal of Haematology·S L JanesA H Goodall
Jan 1, 1995·Cell Motility and the Cytoskeleton·E L Bearer
Oct 1, 1996·Haemostasis·J W Akkerman, G van Willigen
Aug 5, 1997·Proceedings of the National Academy of Sciences of the United States of America·J GabbetaA K Rao
Sep 20, 1997·Nature·S OffermannsM I Simon
Aug 11, 2000·Biological Chemistry·S Offermanns
Feb 13, 2001·European Journal of Pharmacology·A BaurandC Gachet
Feb 28, 2002·The Journal of Pharmacology and Experimental Therapeutics·Ronald J Shebuski, Kenneth S Kilgore
Nov 2, 2002·Hypertension·Janelle R KeysAndrea D Eckhart
Jun 24, 2003·The Journal of Antibiotics·Masatoshi TaniguchiShin-ichi Tsukamoto
Sep 2, 2004·The Journal of Biological Chemistry·Jun TakasakiMasato Kobori

❮ Previous
Next ❯

Citations

Jul 1, 2009·Proceedings of the National Academy of Sciences of the United States of America·Noritaka ImamachiSang-Kyou Han
Jan 24, 2013·The Journal of Biological Chemistry·Bhanu Kanth ManneSatya P Kunapuli
Oct 6, 2015·Scientific Reports·Jakobus van UnenJoachim Goedhart
Mar 4, 2015·Platelets·Vaishali InamdarSatya P Kunapuli
Jan 31, 2015·Arteriosclerosis, Thrombosis, and Vascular Biology·Paul A GurbelUdaya S Tantry
Dec 1, 2009·Journal of Neurochemistry·Marie-Louise MoldrupJan Fahrenkrug
Apr 7, 2015·The Journal of Clinical Investigation·Liming WangRobert F Spurney
Sep 15, 2017·Science Translational Medicine·Michaela MattheyDaniela Wenzel
May 13, 2010·Journal of Biomolecular Screening·Alexandre NesterovEdward Cannon
Aug 31, 2006·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Tomihisa KawasakiJun Takasaki
Jun 21, 2019·Medicinal Research Reviews·Hang ZhangKristian Strømgaard
Apr 22, 2015·Current Treatment Options in Cardiovascular Medicine·Rahil RafeedheenPaul A Gurbel
Nov 25, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tyler D HitchmanYu Chen
Feb 28, 2021·The Journal of Biological Chemistry·Julian PattEvi Kostenis
Mar 10, 2016·Biochemical Pharmacology·Zhan-Guo Gao, Kenneth A Jacobson
Mar 10, 2018·European Journal of Pharmacology·Mohammed Akli Ayoub

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.